Publication:

Smurf1 regulation of DAB2IP controls cell proliferation and migration

Loading...
Thumbnail Image

Date

2016

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

Impact Journals LLC
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Li, Xiaoning, Xiangpeng Dai, Lixin Wan, Hiroyuki Inuzuka, Liankun Sun, and Brian J. North. 2016. “Smurf1 regulation of DAB2IP controls cell proliferation and migration.” Oncotarget 7 (18): 26057-26069. doi:10.18632/oncotarget.8424. http://dx.doi.org/10.18632/oncotarget.8424.

Abstract

Tumor cell proliferation, survival and migration are regulated by the deletion of ovarian carcinoma 2/disabled homolog 2 (DOC-2/DAB2) interacting protein (DAB2IP), a tumor suppressor that serves as a scaffold protein for H-Ras and TRAF2. Importantly, the oncogenic histone methyl-transferase EZH2 epigenetically down-regulates DAB2IP in a variety of tumors. Recently, we demonstrated that DAB2IP is negatively regulated by Akt-dependent phosphorylation and SCFFbw7-mediated degradation. Here, we further identify the oncoprotein Smurf1, an E3-ubiquitin ligase, as a novel negative regulator of DAB2IP. Smurf1-mediated cellular proliferation and migration are largely dependent on the presence of DAB2IP, suggesting that DAB2IP is a key effector molecule of Smurf1 oncogenic function. Additionally, we identify that similar to DAB2IP, Smurf1 is also a target of phosphorylation by both Akt1 and Akt2 kinases, which enhances Smurf1 abundance, leading to a reduction in DAB2IP. Given the role of DAB2IP in tumorigenesis and metastasis, our data identify Smurf1 as an upstream oncogenic factor that negatively regulates DAB2IP to govern aberrant cell growth and migration.

Description

Research Data

Keywords

DAB2IP, Smurf1, Akt, degradation, cancer

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories